论文信息 - Pulmonary Arterial Hypertension-Related Morbidity Is Prognostic for Mortality. - 字舞流文

Pulmonary Arterial Hypertension-Related Morbidity Is Prognostic for Mortality.

A. Torbicki | H. Ghofrani | G. Simonneau | O. Sitbon | M. Hoeper | V. McLaughlin | V. Tapson | K. Chin | L. Rubin | R. Souza | S. Gaine | I. Lang | T. Pulido | M. Delcroix | P. Verweij | N. Galiè | S. Mehta | R. Channick | P. Jansa | B. Sastry | L. Perchenet | R. Preiss | M. Hoeper | R. Souza | R. N. Channick | L. J. Rubin | Vallerie V. McLaughlin | Kelly M. Chin | Irene M. Lang | Vallerie V Mclaughlin

[1] S. Söderberg,et al. A comprehensive risk stratification at early follow-up determines prognosis in pulmonary arterial hypertension , 2018, European heart journal.

[2] M. Humbert,et al. Risk assessment in pulmonary arterial hypertension , 2018, European Respiratory Journal.

[3] S. Rosenkranz,et al. Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model , 2017, European Respiratory Journal.

[4] M. Humbert,et al. Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension , 2017, European Respiratory Journal.

[5] M. Humbert,et al. Initial dual oral combination therapy in pulmonary arterial hypertension , 2016, European Respiratory Journal.

[6] Simon Gibbs,et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension , 2015, European Respiratory Journal.

[7] J. Barberà,et al. Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. , 2015, The New England journal of medicine.

[8] H. Ghofrani,et al. Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension , 2015, European Respiratory Journal.

[9] H. Ghofrani,et al. Selexipag for the Treatment of Pulmonary Arterial Hypertension. , 2014, The New England journal of medicine.

[10] T. Fleming,et al. New trial designs and potential therapies for pulmonary artery hypertension. , 2013, Journal of the American College of Cardiology.

[11] R. Benza,et al. Evaluation of the predictive value of a clinical worsening definition using 2-year outcomes in patients with pulmonary arterial hypertension: a REVEAL Registry analysis. , 2013, Chest.

[12] Z. Jing,et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. , 2013, The New England journal of medicine.

[13] T. Welte,et al. The prognostic impact of follow-up assessments in patients with idiopathic pulmonary arterial hypertension , 2011, European Respiratory Journal.

[14] U. Dafni. Landmark Analysis at the 25-Year Landmark Point , 2011, Circulation. Cardiovascular quality and outcomes.

[15] T. Fleming,et al. End points and clinical trial design in pulmonary arterial hypertension. , 2004, Journal of the American College of Cardiology.

[16] A. Torbicki,et al. End points and clinical trial designs in pulmonary arterial hypertension: clinical and regulatory perspectives. , 2004, Journal of the American College of Cardiology.

[17] J R Anderson,et al. Analysis of survival by tumor response. , 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.